Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2026)

Ginkgo Bioworks Holdings has reported Common Equity for 8 years, with the latest figure at $443.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 31.55% year-over-year to $443.2 million; the trailing twelve-month figure through Mar 2026 stood at $443.2 million (down 31.55% YoY), and the FY2025 full-year result was $508.6 million, down 28.97% from the prior year.
• Common Equity for Q1 2026 stood at $443.2 million, down from $508.6 million in the prior quarter.
• The five-year high for Common Equity was $1.7 billion in Q4 2022, with the low at $443.2 million in Q1 2026.
• Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $987.3 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity jumped 341.91% — and 2024, when it sank 44.59%.
• Ginkgo Bioworks Holdings' Common Equity stood at $1.7 billion in 2022, then tumbled by 36.81% to $1.1 billion in 2023, then sank by 34.73% to $716.1 million in 2024, then retreated by 28.97% to $508.6 million in 2025, then slipped by 12.87% to $443.2 million in 2026.
• The last three Common Equity figures came in at $443.2 million (Q1 2026), $508.6 million (Q4 2025), and $559.8 million (Q3 2025), per Business Quant data.